Find Your Broker
Share Name Share Symbol Market Type Share ISIN Share Description
Futura Medical LSE:FUM London Ordinary Share GB0033278473 ORD 0.2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +1.225p +10.63% 12.75p 12.50p 13.00p 14.35p 11.525p 11.525p 3,977,328 15:59:03
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.4 -4.8 -3.2 - 26.09

Futura Medical Share Discussion Threads

Showing 16151 to 16174 of 16700 messages
Chat Pages: Latest  656  655  654  653  652  651  650  649  648  647  646  645  Older
DateSubjectAuthorDiscuss
24/7/2018
08:39
guessing it is disappointing but can be explained by the BoD having a long history of signing many distributorship deals which amount to nothing in the end - hence the share price performance, or lack of, I should say
mikethebike4
24/7/2018
08:36
rrr Yes it takes a long time then add on about 18 months (previous FUM chat) for preparation of a market launch. The clock stops on questions re the 210 days. It didn't talk outperform in the RNS just Futura has achieved statistically significant pain relief in a clinical study compared with placebo for TPR100, which is a non-steroidal anti-inflammatory drug ("NSAID") using diclofenac as its active ingredient. I'd have to have a look to see if it outperforms the world number 1 out that's what they were indicating some time back.
superg1
23/7/2018
23:22
Positively delighted as news is a bonus and no share price movement as the really important RNS will contain med 2002 details.Jo Stalin no boom expected till med 2002 licensing deal or TTT is encapsulated in the RNs
shakin not stirred
23/7/2018
15:39
Given that we had been waiting on an update confirming that T&R had completed the application to UK Medicines and Healthcare products Regulatory Agency it's very disappointing to see the complete lack of positive share price action. The RNS brings the commercial release of TPR100 considerably closer and the importance of the RNS seems to have completely been overlooked.
guessing
23/7/2018
14:13
Was that it? The Booooommmmm was deafening!
joestalin
23/7/2018
13:27
They will receive milestone payments well before then. More importantly they will have another product commercialised and more to follow according to today's Rns. 'The co has a habit of clusters of news. I won't risk being out of this stock on The basis a med2002 deal will see the share price multiply. Tick tock..
j777j
23/7/2018
12:36
I guess it's widely seen as yet another jam tomorrow RNS. As it is. Track record of actually getting anything to market and selling it is poor. I expect this will be approved, but that could be 30 weeks plus away (but might be sooner) and then we wait to see if it actually gets to the shops this time. If marketed well at a reasonable price I think it should sell well in time as it does seem to have considerable advantages over existing. If all that happens then FUM should make some money at last. But you can see why people aren't leaping in today. rrr
rrr
23/7/2018
11:37
Well the market is clearly underwhelmed by the RNS.
weildy2
23/7/2018
10:56
If this is solely a UK application then it seems that: "The application process takes up to 210 days, excluding time taken to provide further information or data required." hTTps://www.gov.uk/guidance/apply-for-a-licence-to-market-a-medicine-in-the-uk#national
rrr
23/7/2018
09:41
You may well be right S0llis! Trouble is at the moment she'd find it difficult to get hold of any.
rrr
23/7/2018
09:39
My post was a light-hearted way of saying that potential and actual are different things. We have heard from Futura about potential many times but actual sales and income have been minimal.
rrr
23/7/2018
09:37
rrr Not too sure of that. I think she would have needed an adequate supply of MED2002 and occasional CSD500 to raise her partners' performance to hers.
s0lis
23/7/2018
09:17
"An ounce of performance is worth pounds of promises." - Mae West. I don' think she'd have invested in Futura.
rrr
23/7/2018
09:04
j7 "TPR100 is licensed in the UK to Thornton & Ross, one of the UK's largest consumer healthcare companies and a subsidiary of STADA. Thornton & Ross holds exclusive rights to manufacture, distribute and market TPR100 in the UK for the lifetime of the product's patents, which run to 2028 in the UK." let's hope they come up with the goods market-wise rather than just sit on it like so many so-called distributors Futura have agreements with ! just remember the CSD500/Blue Diamond debacle
mikethebike4
23/7/2018
08:37
More news to follow.....TPR100 has the potential to be a best-in-class treatment in which the topical formulation and efficacy profile very successfully meet patient needs. We continue in commercial discussions with several potential distribution partners for territories outside of the UK.So pain gel market worth nearly $3 billionMed2002 potentially $1 billion salesWatch this space :-)~
j777j
23/7/2018
08:16
Chart looks nice if you have a short position. What a dog this is.
greedfear
23/7/2018
08:15
Yes, well the market seems to be excited too. No further updates? Hm.
greedfear
23/7/2018
08:00
Dec 2017".......This means that the best-in-class topical treatment should be the first choice for doctors in the initial treatment of pain and therefore represents a substantial opportunity in a market with global sales estimated at US$2.9 billion."
j777j
23/7/2018
07:48
a small step - lets hope it gets to market quickly and earns us a few bob !
mikethebike4
23/7/2018
06:34
Good news.
rrr
23/7/2018
06:26
Futura Medical plc("Futura" or the "Company") TPR100: UK Regulatory Submission Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, is pleased to announce that its UK commercialisation partner for TPR100, one of the Company's novel topical pain relief products, has filed the product's marketing authorisation application with the UK Medicines and Healthcare products Regulatory Agency. TPR100 is licensed in the UK to Thornton & Ross, one of the UK's largest consumer healthcare companies and a subsidiary of STADA. Thornton & Ross holds exclusive rights to manufacture, distribute and market TPR100 in the UK for the lifetime of the product's patents, which run to 2028 in the UK. TPR100, which benefits from the rapid skin permeation rates offered by Futura's proprietary DermaSys® delivery system, will be launched, once approved, as an over-the-counter and general sales ledger product for the local symptomatic relief of pain and inflammation in:·      trauma of the tendons, ligaments, muscles and joints, e.g. from sprains, strains and bruises·      localised forms of soft tissue rheumatism. Futura has achieved statistically significant pain relief in a clinical study compared with placebo for TPR100, which is a non-steroidal anti-inflammatory drug ("NSAID") using diclofenac as its active ingredient. James Barder, Chief Executive of Futura Medical, said: "The filing of this marketing authorisation application marks a very important step in the commercialisation of TPR100 in the UK. We are delighted by the commitment to the product shown by Thornton & Ross and we look forward to the product's launch in due course. "TPR100 has the potential to be a best-in-class treatment in which the topical formulation and efficacy profile very successfully meet patient needs. We continue in commercial discussions with several potential distribution partners for territories outside of the UK."  For any further information please contact:  Futura Medical plc James Barder, Chief Executive Tel: +44 (0)1483 685 670mail to: james.barder@futuramedical.comwww.futuramedical.com   N+1 Singer (Nominated Adviser and Broker) Aubrey Powell / Liz Yong Tel:+44 (0) 20 7496 3000  For media enquiries please contact:  Buchanan Mark Court / Sophie Wills / Tilly AbrahamTel: +44 (0)20 7466 5000   Notes to Editors Futura Medical plc Futura Medical is a pharmaceutical group that develops innovative products for both prescription and consumer healthcare markets. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups. Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. END  MSCUUSWRWRABUAR
j777j
21/7/2018
09:44
Meanwhile, I sold here, Boo was below 1.50 when it was heavily shorted. I sold that too early at 1.86, only a cheeky 20% in a few weeks but I sent the money into SOS at 18p (some of us went into SOS from here Mike), currently up 80%. So I’ve more than doubled my FUM money in the time FUM has dropped ~20%. So whilst you’re all waiting for the unicorn to arrive there’s real companies selling real products and building real businesses. Didn’t someone on here quote MB at the AGM as saying “we’re [FUM] not a commercial company”? Unbelievable. Sure FUM *might* strike a great deal and rocket. But history tells us it probably won’t and the company admitted they’re not in it to make money. Most likely, more delays and more dilution. Directors keep getting paid though. I pity the fools (and I used to be one) who are long here.
mauricemonkey
20/7/2018
19:12
'What I will not do is buy more to bring my cost average down nor will I listen to unsubstantiated comments on this board that there are unlimited gains just around the corner.' Totally agree.
rrr
20/7/2018
17:42
It could be argued that the touch paper is already lit and is smouldering albeit slowly at this point. At 31 Dec. 2017 there was £8.36m cash or cash equivalent showing on the balance sheet. The 2017 loss was £4.8m and in 2018 it is unlikely that the current income rate will give a higher yearly income. The development costs are likely to be higher in 2018. All of which points to a 2018 cash burn well in excess of £4.8m. This leaves two alternatives for salvation. Either quickly find a development partner who will fund the development costs. This may be difficult as history shows over many many years there have been unconsumated flirtations with most of the big players. Or try to raise further funds by dangling yet again some juicy carrots. This may not work as it is soon after the last in-gathering of cash. We can all try to re-assure each other by saying 'look at the rewards there will be one day'. Perhaps we should substitute might for will. FUM had £37m of accumulated losses at the end of 2017. Many of us have over the years been tempted to say 'the share price is currently very low I can average down'. Some have successfully sold at a profit but many of us have held on for the gold at the end of the rainbow. Perhaps if we see the price falling further, before we buy more, we should say 'my holding is 40,000 @ 25p, do I really want to keep £10,000 invested here'. The problem is many of us have held too long and lost too much. Me, I am half tempted to leave it where it is but write it off in my mind and if one day it all comes right I will be pleasantly surprised. What I will not do is buy more to bring my cost average down nor will I listen to unsubstantiated comments on this board that there are unlimited gains just around the corner. I hope Mr Barder achieves his dream before he retires and I hope that there will be solid eveidence of success soon, not for his sake but for mine and all other small shareholders, especiaaly those who have shown many years of patience. But if it goes boom it goes boom.
pennywise
Chat Pages: Latest  656  655  654  653  652  651  650  649  648  647  646  645  Older
Your Recent History
LSE
FUM
Futura Med..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190122 16:18:58